Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 147,785
  • Shares Outstanding, K 1,219,347
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,840 K
  • EBIT $ 9 M
  • EBITDA $ 11 M
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.02 on 10/15/24
  • Next Earnings Date 10/28/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1169 +0.51%
on 11/15/24
0.1505 -21.93%
on 10/21/24
-0.0310 (-20.88%)
since 10/18/24
3-Month
0.1120 +4.91%
on 08/21/24
0.2090 -43.78%
on 09/05/24
-0.0070 (-5.62%)
since 08/16/24
52-Week
0.1110 +5.86%
on 08/06/24
0.4180 -71.89%
on 12/07/23
-0.0625 (-34.72%)
since 11/17/23

Most Recent Stories

More News
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

CYDY : 0.1175 (-3.05%)
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories

CYDY : 0.1175 (-3.05%)
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

CYDY : 0.1175 (-3.05%)
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques

CYDY : 0.1175 (-3.05%)
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

CYDY : 0.1175 (-3.05%)
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf...

CYDY : 0.1175 (-3.05%)
CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf...

CYDY : 0.1175 (-3.05%)
CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...

CYDY : 0.1175 (-3.05%)
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV ...

CYDY : 0.1175 (-3.05%)
CytoDyn to Hold Webcast to Provide a Quarterly Company Update

VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company...

CYDY : 0.1175 (-3.05%)

Business Summary

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has...

See More

Key Turning Points

3rd Resistance Point 0.1257
2nd Resistance Point 0.1239
1st Resistance Point 0.1207
Last Price 0.1175
1st Support Level 0.1157
2nd Support Level 0.1139
3rd Support Level 0.1107

See More

52-Week High 0.4180
Fibonacci 61.8% 0.3007
Fibonacci 50% 0.2645
Fibonacci 38.2% 0.2283
Last Price 0.1175
52-Week Low 0.1110

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar